KM Research Hub
← 返回论文库
待处理 入排:排除 图源:待检查

Inoperable Early-Stage Non-Small-Cell Lung Cancer: Stereotactic Ablative Radiotherapy and Rationale for Systemic Therapy.

Megan E Daly

J Clin Oncol 40(6) 539-545

PMID34985921
PMCID-
DOI10.1200/JCO.21.01611
发表日期2022-01-05
摘要

摘要

Stereotactic ablative radiotherapy (SABR) is the standard treatment for medically inoperable, early-stage non-small-cell lung cancer. SABR results in high rates of in-field tumor control, but among larger and more biologically aggressive tumors, regional and distant failures are problematic. Cytotoxic chemotherapy is rarely used in this patient population and the benefit is unclear. Alternative systemic therapy options with a milder side-effect profile are of considerable interest, and several randomized phase III trials are currently testing immune checkpoint inhibitors in this setting. We review the rationale, data, and ongoing studies evaluating systemic therapy in medically inoperable, early-stage non-small-cell lung cancer treated with SABR.

KM 提取结果

0 个 Figure · 0 个 KM 面板

尚未提取到 KM 面板。